Kestrel is discovering and developing new molecules to treat intractable cancers. We are starting with potent inhibitors of pan-oncogenic-RAS.
We rely on exceptional science, and our focus, always, is on patients.
Mutations in the RAS family of genes (KRAS, HRAS and NRAS) are present in over 30% of all cancer. A RAS mutation is the most frequent oncogenic alteration in cancer. Kestrel’s goal is to develop molecules active regardless of RAS isoform, mutation, or tumor histology, to have the capability of potentially addressing all RAS mutations in all tumor types.
CT scan of a patient with metastatic pancreatic cancer. More than 95% of these tumors carry RAS mutations, and most are presently not treatable.
The RAS protein is a small molecule implicated widely in cancer cell signaling processes and broadly in the genesis of cancer. Data in hand from our RAS program demonstrate that our inhibitors are active against pan-oncogenic-RAS, bind to RAS, and inhibit its activation.
At Kestrel we recognize the success of our business depends upon the excellence of our people. We are dedicated to recruiting exceptional talent for our team.